Clinical trials in patients with biochemically relapsed prostate cancer

BJU International

Volumn 97, Issue 5, 2006, Pages 905-910

  Lin, Amy M ^a   Rini, Brian I ^b   Small, Eric J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; CYTOSTATIC AGENT; CYTOTOXIC AGENT; PLACEBO; PROSTATE SPECIFIC ANTIGEN; ROSIGLITAZONE;

ANEMIA; BLOOD LEVEL; CANCER HORMONE THERAPY; CANCER INVASION; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PATIENT; CANCER RELAPSE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; DISEASE DURATION; DISEASE FREE SURVIVAL; DISEASE MARKER; DRUG INDUCED CANCER; FATIGUE; HIGH RISK POPULATION; HUMAN; LIBIDO DISORDER; LYMPH NODE METASTASIS; METASTASIS POTENTIAL; METHODOLOGY; MUSCLE ATROPHY; OSTEOPOROSIS; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RECURRENCE RISK; RISK ASSESSMENT; SHORT SURVEY; STANDARDIZATION; SYSTEMIC THERAPY; TREATMENT FAILURE;

CLINICAL TRIALS; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS;

EID: 33645746897     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06124.x     Document Type: Short Survey

References (30)

1. Jemal A Tiwari RC Murray T et al. Cancer statistics, 2004 CA Cancer J Clin 2004 54 8 29
2. Moul JW Prostate specific antigen only progression of prostate cancer J Urol 2000 163 1632 42
3. Pound CR Partin AW Eisenberger MA Chan DW Pearson JD Walsh PC Natural history of progression after PSA elevation following radical prostatectomy JAMA 1999 281 1591 7
4. Eisenberger MA Partin AW Ond C Roostelaar CV Epstein J Walsh PC Natural history of progression of patients with biochemical (PSA) relapse following radical prostatectomy Update Proc ASCO 2003 22 380
5. Partin AW Eisenberger MA Sinibaldi VJ Humphreys E Mangold LA Walsh PC Prostate specific antigen doubling time (PSA-DT) predicts for distant failure and prostate cancer specific survival (PCSS) in men with biochemical relapse after radical prostatectomy (RP) Proc ASCO 2004 22 (14S
6. Jhaveri FM Zippe CD Klein EA Kupelian PA Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-year results Urology 1999 54 884 90
7. D'Amico AV Moul J Carroll PR Sun L Lubeck D Chen MH Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy J Urol 2004 172 S42 7
8. D'Amico AV Whittington R Malkowicz SB et al. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer J Clin Oncol 1999 17 168 72
9. Partin AW Kattan MW Subong EN et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update JAMA 1997 277 1445 51
10. Kattan MW Zelefsky MJ Kupelian PA et al. Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer J Clin Oncol 2003 21 4568 71
11. Stephenson AJ Aprikian AG Souhami L et al. Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer Urology 2002 59 652 6
12. Choo R Klotz L Deboer G Danjoux C Morton GC Wide variation of prostate-specific antigen doubling time of untreated, clinically localized, low-to-intermediate grade, prostate carcinoma BJU Int 2004 94 295 8
13. Stephenson AJ Shariat SF Zelefsky MJ et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy JAMA 2004 291 1325 32
14. Ward JF Zincke H Bergstralh EJ Slezak JM Blute ML Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy J Urol 2004 172 2244 8
15. Srinivas S Balu V King C Utility of serum prostate specific antigen doubling time (PSADT) in patients with androgen-independent prostate cancer ASCO Prostate Cancer Symposium 2005 Abstract 299
16. Semeniuk R Venner PM Hanson J North SA A retrospective review of prostate specific antigen doubling time (PSADT) in men with hormone refractory prostate cancer (HRPC) ASCO Prostate Cancer Symposium 2005 Abstract 292
17. Albertsen PC Hanley JA Penson DF Fine J Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation J Urol 2004 171 2221 5
18. D'Amico AV Cote K Loffredo M Renshaw AA Schultz D Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer J Clin Oncol 2002 20 4567 73
19. Zagars GK Pollack A Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer Radiother Oncol 1997 44 213 21
20. Roberts SG Blute ML Bergstralh EJ Slezak JM Zincke H PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer Mayo Clin Proc 2001 76 576 81
21. Zelefsky MJ Ben-Porat L Scher HI et al. Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer J Clin Oncol 2005 23 826 31
22. Anonymous. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group Br J Urol 1997 79 235 46
23. Messing EM Manola J Sarosdy M Wilding G Crawford ED Trump D Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer N Engl J Med 1999 341 1781 8
24. Schroder FH Endocrine treatment of prostate cancer - recent developments and the future. Part 1: maximal androgen blockade, early vs delayed endocrine treatment and side-effects BJU Int 1999 83 161 70
25. Grossfeld GD Li YP Lubeck DP Carroll PR Patterns of failure after primary local therapy for prostate cancer and rationale for secondary therapy Urology 2002 60 Suppl. 3 57 63
26. Scher HI Eisenberger M D'Amico AV et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group J Clin Oncol 2004 22 537 56
27. Soergel TM Koch MO Foster RS et al. Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy J Urol 2001 166 2198 201
28. Ross PL Mahmud S Stephenson AJ Souhami L Tanguay S Aprikian AG Variations in PSA doubling time in patients with prostate cancer on 'watchful waiting': value of short-term PSA-DT determinations Urology 2004 64 323 8
29. Smith MR Manola J Kaufman DS et al. Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy Cancer 2004 101 1569 74
30. Bubley GJ Carducci M Dahut W et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group J Clin Oncol 1999 17 3461 7